Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting

CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) --  Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented five posters on its immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms as well as its enzymatic synthesis manufacturing at the American Society of Gene and Cell Therapy (ASGCT) 27^th Annual Meeting. A sixth presentation on the company’s ctLNP platform will be discussed in an oral presentation on Saturday, May 11.

Read more at globenewswire.com